Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05201404 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Study acronym: LIVERATION
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 29, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 2025 to Feb 2026
    • Study completion date: Oct 2025 to Oct 2026
    v10
  2. Re-verified, no change to tracked fieldsv9
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2023 to Mar 15, 2023
    • Study sites revised (32)
    v8
  4. Start date: Jan 2023 to Mar 2023v7
  5. Study sites: 25 to 32v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Oct 2022 to Jan 2023v5
  2. Start date: Apr 2022 to Oct 2022
    • Study sites: 1 to 25
    v4
  3. Start date: Feb 2022 to Apr 2022v3
  4. Secondary endpoints: 5 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.
Trial Details
NCT Number NCT05201404
Lead Sponsor Can-Fite BioPharma
Conditions
(from sponsor)		 Hepatocellular Carcinoma, Cirrhosis
Related terms Carcinoma, Hepatocellular, Fibrosis, Liver Neoplasms
Enrollment 471 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov